Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Maria Giovanna Lupo; Diletta Arcidiacono; Alice Zaramella; Fabio Fimiani; Paolo Calabrò; Angelo Baldassare Cefalù; Maurizio Averna; Laura D'Erasmo; Marcello Arca; Sara De Martin; Alberto Zambon; Nicola Ferri

doi:10.1016/j.athplu.2021.05.001

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Atheroscler Plus. 2021 Jun 19:43:7-9. doi: 10.1016/j.athplu.2021.05.001. eCollection 2021 Sep.

Authors

Affiliations

¹ Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padua, Italy.
² Digestive Endoscopy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
³ Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
⁴ Istituto Oncologico Veneto IOV-IRCCS, Padova, Italia.
⁵ A.O.R.N. Sant'Anna e San Sebastiano, Caserta Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.
⁶ Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.
⁷ Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy.
⁸ Department of Medicine, University of Padova, Padua, Italy.

Abstract

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an anti-inflammatory effect.

Keywords: Familial hypercholesterolemia; Lomitapide; lp(a); pcsk9.